Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Peter Strack"'
Autor:
Robert N Booher, Harold Hatch, Brian M Dolinski, Thi Nguyen, Lauren Harmonay, Ali-Samer Al-Assaad, Mark Ayers, Michael Nebozhyn, Andrey Loboda, Heather A Hirsch, Theresa Zhang, Bin Shi, Carrie E Merkel, Minilik H Angagaw, Yaolin Wang, Brian J Long, Xianlu Q Lennon, Nathan Miselis, Vincenzo Pucci, James W Monahan, Junghoon Lee, Anna Georgieva Kondic, Eun Kyung Im, David Mauro, Rebecca Blanchard, Gary Gilliland, Stephen E Fawell, Leigh Zawel, Alwin G Schuller, Peter Strack
Publikováno v:
PLoS ONE, Vol 9, Iss 10, p e108371 (2014)
Dinaciclib is a potent CDK1, 2, 5 and 9 inhibitor being developed for the treatment of cancer. Additional understanding of antitumor mechanisms and identification of predictive biomarkers are important for its clinical development. Here we demonstrat
Externí odkaz:
https://doaj.org/article/b410584fec734e0e84be6d52d5590862
Autor:
Anirban Maitra, Barry D. Nelkin, Nilofer Azad, Peter Strack, Robert Booher, Rajat Bannerji, Shinichi Yabuuchi, Venugopal Chenna, Tikva Dadon, Chaoxin Hu
Supplementary Figures S1, S2. Supplementary Figure 1 shows pharmacodynamic biomarkers for two of the pancreatic cancer subcutaneous patient-derived xenografts. Supplementary Figure 2 shows necropsy, indicating significantly decreased metastases in an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3497d41730993305078a5d953c2fcd0b
https://doi.org/10.1158/1535-7163.22502937.v1
https://doi.org/10.1158/1535-7163.22502937.v1
Autor:
Anirban Maitra, Barry D. Nelkin, Nilofer Azad, Peter Strack, Robert Booher, Rajat Bannerji, Shinichi Yabuuchi, Venugopal Chenna, Tikva Dadon, Chaoxin Hu
Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b601abb8eb7b65afcfc832ceac946f36
https://doi.org/10.1158/1535-7163.22502940.v1
https://doi.org/10.1158/1535-7163.22502940.v1
Autor:
Yan Wang, Erick J. Morris, Richard E. Middleton, Paul T. Kirschmeier, Leigh Zawel, Cynthia Seidel-Dugan, Pasi A. Jánne, Kwok-Kin Wong, Kumiko Nagashima, Heather Hirsch, Steven Ripley, Chris Hulton, Weiqun Zhang, Rossana Chung, Stephen Wu, Peter Strack, Thi T. Nguyen, Brian Dolinski, Jongwon Lim, Rafael Fernandez, Haiyan Yan, Qi Pan, Asli Muvaffak
PDF file - 1334KB, S1. IC50 values of TBK1 inhibitors Compound number 5, Compound number 4 and Compound number 3 from the selected PDAC, colorectal cancer and NSCLC cancer cell lines using are shown. Table 1S. List of shRNAs Targeting TBK1 Table 2S.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98442b5d4353d94a24d08eb4fa097ec2
https://doi.org/10.1158/1541-7786.22511083
https://doi.org/10.1158/1541-7786.22511083
Autor:
D. Gary Gilliland, Jannik N. Andersen, Peter Strack, Kumiko Nagashima, Pamela M. Carroll, Erica M. Cook, Thi D.T. Nguyen, Marc Ferrer, Erick J. Morris, Bryan Severyn, Andrey Loboda, Jeff Hermes, Michelle A. Cleary, Sriram Sathyanarayanan, Bill Arthur, Yair Benita, Lixia Li, G. Naumov, Michael D. Altman, James Watters, Matthew Tudor
Publikováno v:
SLAS Discovery. 21:989-997
The RAS-MAPK pathway controls many cellular programs, including cell proliferation, differentiation, and apoptosis. In colorectal cancers, recurrent mutations in this pathway often lead to increased cell signaling that may contribute to the developme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::074c2545c65eac59bf852e6e035b3ecb
https://doi.org/10.1177/1087057116658646
https://doi.org/10.1177/1087057116658646
Autor:
Donald A. Bergstrom, Luiz M Camargo, Andrey Loboda, Bo Wei, Jeremy Hing, Sanjiv J. Shah, Eva M. Finney, Samuel C. Blackman, Radha Railkar, Amy Harman, Peter Strack, Tim Demuth, Gary A. Herman, Jared Lunceford, Keith Q. Tanis, James S. Hardwick, Joel A. Klappenbach, James Watters, Robert Iannone, Alexei A. Podtelezhnikov
Publikováno v:
Clinical Pharmacology & Therapeutics. 99:370-380
γ-Secretase mediates amyloid production in Alzheimer's disease (AD) and oncogenic activity of Notch. γ-Secretase inhibitors (GSIs) are thus of interest for AD and oncology. A peripheral biomarker of Notch activity would aid determination of the the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c928c8085458739b360786c67c6df537
https://doi.org/10.1002/cpt.335
https://doi.org/10.1002/cpt.335
Autor:
Raymond E. Gibson, Christopher T. Winkelmann, Christopher Ware, Domenico Coppola, Pradip K. Majumder, Christopher Winter, Edwin A. Clark, Peter Strack, Jennifer Tammam, Timothy Sullivan, Clay L. Efferson, Giuseppe Mesiti, Saverio Giampaoli, Shailendra Patel, Carolyn A. Buser, John F. Reilly, Timothy J. Yeatman, Giulio Draetta
Publikováno v:
Cancer Research. 70:2476-2484
ERBB2/neu and Notch signaling are known to be deregulated in many human cancers. However, pathway cross-talk and dependencies are not well understood. In this study, we use an ERBB2-transgenic mouse model of breast cancer (neuT) to show that Notch si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eecb7da0b6f9b91edfff25fa32f17082
https://doi.org/10.1158/0008-5472.can-09-3114
https://doi.org/10.1158/0008-5472.can-09-3114
Autor:
Peter Strack, Richard S. Larson, Jennifer O'Neil, Alejandro Gutierrez, Harald von Boehmer, Takaomi Sanda, Yebin Ahn, Stuart S. Winter, Donna Neuberg, Xiaoyu Li, Christopher Winter, A. Thomas Look
Publikováno v:
Blood. 115:1735-1745
To identify dysregulated pathways in distinct phases of NOTCH1-mediated T-cell leukemogenesis, as well as small-molecule inhibitors that could synergize with or substitute for γ-secretase inhibitors (GSIs) in T-cell acute lymphoblastic leukemia (T-A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6407a79706af08ae430b33444f9e588f
https://doi.org/10.1182/blood-2009-07-235143
https://doi.org/10.1182/blood-2009-07-235143
Autor:
Christopher Winter, X Dai, Christopher Ware, Jennifer O'Neil, Candia M. Kenific, John F. Reilly, J Gorenstein, George N. Nikov, Peter Strack, Nancy E. Kohl, Clay L. Efferson, KJ Leach, J Hardwick, Han Sang Kim, C Elbi, Jennifer Tammam, Giulio F. Draetta, Kaiko Kunii, T Look, Lht Van der Ploeg, J Zhao, Sudhir Rao, Pradip K. Majumder, Xianlu Qu, Martin L. Scott, L Bristow, Minilik Angagaw
Publikováno v:
British Journal of Pharmacology. 158:1183-1195
Background and purpose: γ-Secretase inhibitors (GSIs) block NOTCH receptor cleavage and pathway activation and have been under clinical evaluation for the treatment of malignancies such as T-cell acute lymphoblastic leukaemia (T-ALL). The ability of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::21d7e46cb8e8f8bf76892f0c3e8dcfb1
https://doi.org/10.1111/j.1476-5381.2009.00389.x
https://doi.org/10.1111/j.1476-5381.2009.00389.x
Autor:
Stefan Krauss, Michael R. Tota, Nicole Ginanni, Margaret Wu, Peter Strack, Nancy E. Kohl, Nathan Bays, Victoria M. Richon, Eric Bachman, Yanai Zhan
Publikováno v:
Clinical Cancer Research. 14:5735-5742
Purpose: For many tumor cells, de novo lipogenesis is a requirement for growth and survival. A considerable body of work suggests that inhibition of this pathway may be a powerful approach to antineoplastic therapy. It has recently been shown that in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::452835503093428fee32a680e78792bc
https://doi.org/10.1158/1078-0432.ccr-07-5074
https://doi.org/10.1158/1078-0432.ccr-07-5074